Trial for the drug CT900 which targets ovarian cancer cells expanded into a larger trial

A trial for the drug CT900 (previously called ONX-0801) which targets ovarian cancer cells via a protein called the alpha-folate receptor is being expanded into a larger trial.

The drug could be suitable for women with ovarian cancer for whom chemotherapy has failed, and whose tumours have high levels of the alpha-folate receptor on the surface of cancer cells.

Read full article

Comments (0)

Please verify your action

Comment (maximum 3500 characters) (required)

Add a picture

Notify me when someone makes a comment

First name (required)

Last name (required)

Email (required)

Which country do you live in?

Postcode (required)

Address line 1

Address line 2

Town or city

Keeping In Touch

We would love to keep you posted with news, activities and how you can help in other ways. We'll never sell or swap your details with anybody else. You are free to change your mind at any time. Please indicate how you are happy to be contacted by using the tick boxes below.

Please note that if you are signing up for an online event being run by our partner Ovarian Cancer Action, the contact details that you provide will be passed on to them, so that they can send you information about your event and keep in touch in the ways that you have indicated that you are happy with.

Via email

Via telephone

Via SMS

Via post

Which country do you live in?

Postcode (required)

Address line 1

Address line 2

Town or city

Your Privacy

We will always store your personal details securely. We'll use them to provide the service that you have requested, and communicate with you in the way(s) that you have agreed to. Your data may also be used for analysis purposes, to help us provide the best service possible. For full details see our Privacy Policy.

By submitting this form you are agreeing to our terms and conditions

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Latest

Making a memory box for loved ones

This series of four informal Q&A sessions will look at video recordings, writing, and crafting for your own unique memory boxes.
Our Run for Emma

I’m raising money for Ovacome, who support people living with ovarian cancer and their loved ones. This cause means a lot to me and I hope that you’ll consider supporting their work in any way that you can.
Get crafty with Ovacome: felt animals

Join us for our next craft session, where we'll be making stuffed felt starfish toys, using various sewing techniques.
NICE approves combination of olaparib plus bevacizuman (Avastin) for ovarian cancer

The National Institute for Health and Care Excellence (NICE) recently approved the drugs olaparib plus bevacizumab (Avastin) for use within the Cancer Drugs Fund (CDF).